Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

Aldose reductase (AR) has been a long-standing target for treating diabetic complications, but its structural similarity to related enzymes has made selective inhibition difficult. Off-target binding ...

Aldose reductase (AR) inhibition has emerged as a strategic approach to mitigate the microvascular and macrovascular complications that characterise diabetes mellitus. Under hyperglycaemic conditions, ...

Researchers from ICTER have developed a fragment-based drug discovery method combined with microcrystal electron diffraction to design enzyme inhibitors at atomic resolution. The approach aims to ...

In this second of three articles on The Sunday Times top 100 tech companies list, pharmaphorum is focusing on the first nine of 18 start-ups featuring in the hardware category. The list recognises the ...

Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic ...